Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma

Journal of Clinical Oncology

Volumn 17, Issue 8, 1999, Pages 2541-2545

  Stadler, Walter M ^a   Kuzel, Timothy ^a   Shapiro, Charles ^a   Sosman, Jeffery ^a   Clark, Joseph ^a   Vogelzang, Nichlas J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FUMAGILLOL CHLOROACETYLCARBAMATE;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; METASTASIS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VERTIGO;

EID: 0032767386     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.8.2541     Document Type: Article

References (21)

1. Landis SH, Murray T, Bolden S, et al: Cancer Statistics, 1999. CA Cancer J Clin 49:8-31, 1999
2. Stadler WM, Vogelzang NJ: Low dose interleukin-2 in the treatment of metastatic renal cell carcinoma. Semin Oncol 22:67-73, 1995
3. Hawkins MJ: Immunotherapy with high-dose interleukin 2, in Vogelzang NJ, Scardino PT, Shipley WU, et al (eds): Comprehensive Textbook of Genitourinary Oncology. Baltimore, MD, Williams and Wilkins, 1996, pp 242-247
4. Minasian LM, Motzer RJ, Gluck L, et al: Interferon alfa-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368-1375, 1993
5. Negrier S, Escudier B, Lasset C, et al: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338:1272-1278, 1998
6. Chapman AE, Goldstein LJ: Multiple drug resistance: Biologic basis and clinical significance in renal cell carcinoma. Semin Oncol 22:17-28, 1995
7. Kim WJ, Kakehi Y, Kinoshita H, et al: Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP), glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney. J Urol 156:506-511, 1996
8. Boehm T, Folkman J, Browder T, et al: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407, 1997
9. Ingber D, Fujita T, Kishimoto S, et al: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348:555-557, 1990
10. Kusaka M, Sudo K, Fujita T, et al: Potent anti-angiogenic action of AGM-1470: Comparison to the fumagillin parent. Biochem Biophys Res Commun 174:1070-1076, 1991
11. Kusaka M, Sudo K, Matsutani E, et al: Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470) Br J Cancer 69:212-216, 1994
12. Yanase T, Tamura M, Fujita K, et al: Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 53:2566-2570, 1993
13. Fujioka T, Hasegawa M, Ogiu K, et al: Antitumor effects of angiogenesis inhibitor 0-(chloroacetyl-carbamoyl) fumagillol (TNP-470) against murine renal cell carcinoma. J Urol 155:1775-1788, 1996
14. Morita T, Shinohara N, Tokue A: Antitumour effect of a synthetic analogue of fumagillin on murine renal carcinoma. Br J Urol 74:416-421, 1994
15. TNP-470: Information for Clinical Investigators. TAP Holdings, July, 1996
16. Dezube BJ, Von Roenn JH, Holden-Wiltse J, et al: Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS Clinical Trial Group study - AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 16:1444-1449, 1998
17. Kudelka AP, Levy T, Verschraegen CF, et al: A phase I study of TNF-470 administered to patients with advanced squamous cell cancer of the cevix. Clin Cancer Res 3:1501-1505, 1997
18. Bhargava P, Marshall J, Rizvi N, et al: A study of TNP-470 in patients with advanced cancer. Proc Am Assoc Cancer Res 38:1489, 1997 (abstr)
19. Dinney CP, Bielenberg DR, Perrotte P, et al: Inhibition of basic fibroblast growth factor expressin, angiogenesis, and growth of human bladder carcinoma in mice by factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 58:808-814, 1998
20. Cretton-Scott E, Placidi L, McClure H, et al: Pharmacokinetics and metabolism of O-(chloroacetyl-carbamoyl) fumagillol (TNP-470, AGM-1470) in rhesus monkeys. Cancer Chemother Pharmacol 38:117-122, 1996
21. Figg WD, Pluda JM, Lush RM, et al: The pharmacokinetics of TNP-470 a new angiogenesis inhibitor. Pharmacotherapy 17:91-97, 1997